• About
  • Subscribe
  • Advertise
  • Contact
Sunday, July 13, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home Local

Nanodrug macular treatment yields ‘impressive results’

by rhiannon bowman
August 3, 2021
in Local, News, Ophthalmology, Research
Reading Time: 2 mins read
A A
Fluorescein angiography showing the large area of hyperfluorescence of choroidal neovasularization (CNV). Surrounding to CNV, hypofluorescence corresponding to the subretinal haemorrhage can be observed. Single treatment of anti-VEGF failed to control the development of neovascularization.

Fluorescein angiography showing the large area of hyperfluorescence of choroidal neovasularization (CNV). Surrounding to CNV, hypofluorescence corresponding to the subretinal haemorrhage can be observed. Single treatment of anti-VEGF failed to control the development of neovascularization.

Share on FacebookShare on Twitter

 

A leading researcher in Queensland has lauded the efficacy of a pioneering treatment for ocular neovascular disease recently trialled in animals.

Professor Di Yu of the University of Queensland’s Diamantina Institute collaborated with scientists from the Chinese Academy of Sciences and Beijing Chaoyang Hospital to challenge the current standard of treatment for age-related macular degeneration (AMD) and diabetic retinopathy – anti-VEGF injections.

“At the moment, ocular neovascular diseases are treated by a method that suppresses a particular growth factor for vessels, but between 40 and 60% of patients do not respond well,” Yu said.

“Those who do not respond well might exude fluids, have unresolved or new bleeding, thickening or scarring of tissue, or fail to recover functional vision.”

Yu and his collaborators are pioneering a more complex nanodrug which not only delivers an antibody, but simultaneously combats inflammation and identified side effects.

In their study of the novel treatment in animals, published in the journal Nature Biomedical Engineering, volumes of lesions were reduced by 95%.

Dr Yong Tao, chief ophthalmologist at the Department of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University. He is a major collaborator in the study and one of senior authors.

“The efficacy was superb,” Yu said. “The new design allows the nanodrug to concentrate on lesions and deliver lasting benefits.

“With the impressive results, further developments are now under way to translate it into a new therapy,” he said.

Yu said the high prevalence of ocular neovascular disease, with 415 million people at risk of loss of sight through diabetes, and as many as 50 million with AMD, was likely to get worse.

“With an aging population, the number of cases of age-related macular degeneration is expected to increase as much as five-fold by 2040,” he said.

“This new approach will hopefully benefit a large number of patients with age-related macular degeneration or diabetic retinopathy by improving eyesight and preventing blindness.”

More reading

MDFA responds after NSW health chief says eye checks can be deferred

New frontiers in treating late-stage AMD

Anti-VEGF becomes most expensive drug on PBS

Tags: Diamantina InstitutenanodrugProfessor Di YuUniversity of QueenslandUniversity of Queensland Diamantina Institute

Related Posts

So many companies working on so many solutions in IOLs and surgery means it has become evident that there is some nomenclature confusion.  Image: Oktay/stock.adobe.com.

Clearing up nomenclature confusion in IOL lenses

by Dr Peter Sumich
July 13, 2025

Presbyopia management has been the holy grail for intraocular lens technology development for 30 years, but sub-classifying lenses has become...

What the customer wants in a frame will not necessarily be suited to the prescription they end up with. Images: Jacobus Boshoff.

No, you can’t have that frame

by Jacobus Boshoff
July 12, 2025

Jacobus Boshoff on why a good optical dispenser sometimes needs to dish out the harsh truth, and why frame choice...

Myopia is surging around the world, and particularly among children. New studies show that HOYA's DIMS technology can have a lasting impact in treatment. Image: HOYA.

New evidence backs HOYA’s DIMS technology to combat myopia

by Staff Writer
July 11, 2025

HOYA Vision Care has announced new clinical evidence from three key clinical studies highlighting the impact of Defocus Incorporated Multiple...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited